Results 301 to 310 of about 257,826 (338)

Correspondence to: Clinico‐sero‐pathological characteristics of anti‐Ha antisynthetase syndrome

open access: yes
Brain Pathology, EarlyView.
Marie‐Therese Holzer   +5 more
wiley   +1 more source
Some of the next articles are maybe not open access.

Related searches:

Cyclophosphamide and diabetes

Cancer Chemotherapy and Pharmacology, 1981
Little information is available about the effect of cytotoxic drugs on diabetes mellitus. Cyclophosphamide has been reported to be a possible cause of mild diabetes [2], but Kruger [1] described two diabetics whose blood sugar levels fell during treatment with cyclophosphamide.
R. G. Henderson, Robert D. Rubens
openaire   +3 more sources

Assay of Cyclophosphamide

Journal of Pharmaceutical Sciences, 1972
A GLC procedure was developed for the assay of cyclophosphamide raw materials and cyclophosphamide in formulations. Results obtained by this technique are comparable to those obtained by IR spectroscopy. The GLC procedure offers increased accuracy, reproducibility, and precision. The method is more specific and less time consuming than the IR procedure.
C.M. Combs   +4 more
openaire   +3 more sources

Cyclophosphamide in dermatology

Australasian Journal of Dermatology, 2016
AbstractCyclophosphamide is a chemotherapeutic agent which was first discovered in experimental tumours in rats, and it has since been widely used to treat malignancies and severe manifestations of various auto‐immune diseases. High‐dose chemotherapy and continuous daily oral regimens are associated with significant toxicity profiles, but i.v.
Janet Kim, Jonathan Chan
openaire   +3 more sources

Novel class of cyclophosphamide prodrug: Cyclophosphamide spiropiperaziniums (CPSP)

Bioorganic & Medicinal Chemistry Letters, 2006
AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
Qi Sun   +5 more
openaire   +4 more sources

Home - About - Disclaimer - Privacy